Compass Pathways Phase 3 Psilocybin trial results - Psychedelic Stock down 50%?! Emergency podcast!
Description
Compass Pathways ($CMPS) released an interim readout from their Phase 3 trial of Psilocybin (COMP360) for treatment resistant depression (TRD).
The data was positive and highly anticipated by the psychedelic community, but the stock dropped 50% on June 23rd. Brom Rector and Sam Tabone of XEIA Venture Partners react and comment in this emergency podcast.
We discuss:
(0:00 ) - what did the Compass Pathways data readout actually say
(12:00 ) - putting the Compass trial results into context vs SSRIs, Lexapro, Spravato and Ketamine
(19:00 ) - why Compass crashed
(24:00 ) - will Comp360 get FDA approval?
(26:00 ) - will COMP360 be commercially successful?
(30:00 ) - price targets for Compass Pathways $CMPS
(35:00 ) - will Compass get acquired?
(40:00 ) - are we bullish or bearish on Compass?
Learn more about Brom, Sam and XEIA at www.xeiavp.com
![Investing in Psychedelic BioTech [August 2025 webinar replay]](https://s3.castbox.fm/70/e6/a2/62bd7fa7c470b268bd191f457c0ddd8b62_scaled_v1_400.jpg "Investing in Psychedelic BioTech [August 2025 webinar replay]")
United States
